{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.465","value":"-0.036"},{"groupId":"OG001","spread":"0.362","value":"-0.019"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"494"},{"groupId":"OG001","value":"495"}],"units":"Participants"}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.475","value":"-0.078"},{"groupId":"OG001","spread":"0.556","value":"0.001"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"412"},{"groupId":"OG001","value":"410"}],"units":"Participants"}],"title":"Day 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.570","value":"-0.082"},{"groupId":"OG001","spread":"0.958","value":"0.129"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"285"}],"units":"Participants"}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.798","value":"-0.055"},{"groupId":"OG001","spread":"1.037","value":"0.194"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"title":"Day 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.714","value":"-0.042"},{"groupId":"OG001","spread":"0.662","value":"0.094"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"254"},{"groupId":"OG001","value":"273"}],"units":"Participants"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.678","value":"-0.034"},{"groupId":"OG001","spread":"0.511","value":"0.033"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"260"},{"groupId":"OG001","value":"257"}],"units":"Participants"}],"title":"Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"494"},{"groupId":"OG001","value":"495"}],"units":"Participants"}],"description":"Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","dispersionType":"Standard Deviation","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEAN","populationDescription":"The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.","reportingStatus":"POSTED","timeFrame":"Days 1, 3, 5, 8, 11, 15 and 29","title":"Change From Baseline in Creatinine","type":"SECONDARY","unitOfMeasure":"milligrams/deciliter (mg/dL)"}